Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer – Pipeline Review, H2 2016, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 15, 115, 119, 7, 195, 31 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 11, 34 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

3-V Biosciences Inc
4SC AG
AB Science SA
AbbVie Inc
AbGenomics International Inc
Acetylon Pharmaceuticals Inc
Adaptimmune Therapeutics Plc
Adgero Biopharmaceuticals Inc
Aduro BioTech Inc
Advanced Accelerator Applications SA
Advanced Cancer Therapeutics
Advaxis Inc
Advenchen Laboratories LLC
Aeterna Zentaris Inc
Alchemia Ltd
Alethia Biotherapeutics Inc
Almac Discovery Ltd
Alpha Cancer Technologies Inc
Alteogen Inc
Ambrx Inc
Amgen Inc
Anavex Life Sciences Corp
ANP Technologies Inc
AntiCancer Inc
Antoxis Ltd
Apac Biotech Pvt Ltd
Aphios Corp
Aposense Ltd
Aprea AB
Aptevo Therapeutics Inc
arGEN-X BV
ARMO Biosciences Inc
Armour Therapeutics Inc
Arno Therapeutics Inc
Arog Pharmaceuticals Inc
ArQule Inc
Arrien Pharmaceuticals LLC
Arvinas Inc
Ascentage Pharma Group Corp Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Athenex Inc
ATLAB Pharma SAS
AVEO Pharmaceuticals Inc
Avipep Pty Ltd
Azaya Therapeutics Inc
Basilea Pharmaceutica Ltd
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Bio-Path Holdings Inc
BioCancell Ltd
BioMoti Ltd
Bionomics Ltd
BioNTech AG
Biscayne Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Calithera Biosciences Inc
CASI Pharmaceuticals Inc
Cavion LLC
Cellceutix Corp
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Cellular Biomedicine Group Inc
Celon Pharma SA
Celprogen Inc
Celsion Corp
Celyad SA
Ceronco Biosciences
CerRx Inc
Cerulean Pharma Inc
Chipscreen Biosciences Ltd
Cielo Therapeutics Inc
Clovis Oncology Inc
CohBar Inc
Coherus BioSciences Inc
Commence Bio Inc
Compliment Corp
Corcept Therapeutics Inc
Critical Outcome Technologies Inc
CTI BioPharma Corp
Cyclacel Pharmaceuticals Inc
CytRx Corp
CZ BioMed Corp
Deciphera Pharmaceuticals LLC
DEKK-TEC Inc
DelMar Pharmaceuticals Inc
Dr. Reddy's Laboratories Ltd
Ecrins Therapeutics SAS
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Company
Endocyte Inc
EntreChem SL
Epigen Biosciences Inc
Esperance Pharmaceuticals Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Five Prime Therapeutics Inc
Fujifilm Corp
Galena Biopharma Inc
GamaMabs Pharma SA
Ganymed Pharmaceuticals AG
Gene Techno Science Co Ltd
Genelux Corp
Genentech Inc
Generex Biotechnology Corp
Genisphere Inc
Genmab A/S
Genor BioPharma Co Ltd
Gero Corp
Gilead Sciences Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
GlycoNex Inc
Glycotope GmbH
GP Pharm SA
Gradalis Inc
GW Pharmaceuticals Plc
Halozyme Therapeutics Inc
Hanmi Pharmaceuticals Co Ltd
HEC Pharm Co Ltd
Hemispherx Biopharma Inc
Horizon Pharma Plc
Ideaya Biosciences Inc
Ignyta Inc
Ildong Pharmaceutical Co Ltd
IMMD Inc
Immune Design Corp
Immune Pharmaceuticals Inc
Immune Therapeutics Inc
Immunocore Ltd
ImmunoGen Inc
Immunomedics Inc
Immunovaccine Inc
Incyte Corp
Inflection Biosciences Ltd
Innate Immunotherapeutics Ltd
Innate Pharma SA
Inovio Pharmaceuticals Inc
INSYS Therapeutics Inc
Inventiva
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Juno Therapeutics Inc
Karyopharm Therapeutics Inc
Komipharm International Co Ltd
Kyowa Hakko Kirin Co Ltd
Laboratoire HRA Pharma
Lantern Pharma Inc
LegoChem Biosciences Inc
Lidds AB
Lion Biotechnologies Inc
Lixte Biotechnology Holdings Inc
Lymphocyte Activation Technologies SA
Mabion SA
MabVax Therapeutics Holdings Inc
MacroGenics Inc
Mateon Therapeutics Inc
MaxiVAX SA
Mebiopharm Co Ltd
Medestea Research & Production SpA
MediaPharma srl
MedImmune LLC
Medivation Inc
Merck & Co Inc
Merck KGaA
Mersana Therapeutics Inc
Merus NV
Microlin Bio, Inc.
Millennium Pharmaceuticals Inc
Minerva Biotechnologies Corp
Molecular Partners AG
Moleculin Biotech Inc
MolMed SpA
Monopar Therapeutics LLC
Morphotek Inc
Mycenax Biotech Inc
Natco Pharma Ltd
Nektar Therapeutics
Nemucore Medical Innovations Inc
Neovacs SA
Nerviano Medical Sciences Srl
Neurimmune Holding AG
Northwest Biotherapeutics Inc
Novartis AG
NovaTarg Therapeutics Inc
Noviga Research AB
Novogen Ltd
NuCana BioMed Ltd
Oasmia Pharmaceutical AB
OBI Pharma Inc
Omeros Corp
Omnitura Therapeutics Inc
OncBioMune Pharmaceuticals Inc
Oncobiologics Inc
Oncodesign SA
OncoHoldings Inc
Oncolix Inc
Oncolytics Biotech Inc
OncoMed Pharmaceuticals Inc
Oncopeptides AB
OncoTartis Inc
Oncternal Therapeutics Inc
Ono Pharmaceutical Co Ltd
Optimum Therapeutics LLC
ORCA Therapeutics BV
OSE Immunotherapeutics
Oxford BioMedica Plc
OXIS International Inc
Pangaea Biotech SL
Panther Biotechnology Inc
Patrys Ltd
PDS Biotechnology Corp
PEP-Therapy SAS
Pfizer Inc
Pharma Mar SA
PharmAust Ltd
Pharmicell Co Ltd
Plexxikon Inc
Polaris Pharmaceuticals Inc
Precision Biologics Inc
Prima BioMed Ltd
Propanc Health Group Corp
PsiOxus Therapeutics Ltd
Puma Biotechnology Inc
Radius Health Inc
Recepta Biopharma SA
Rexahn Pharmaceuticals Inc
Rgenix Inc
Richter Gedeon Nyrt
Rigontec GmbH
Rosetta Genomics Ltd
Sanofi
Sanofi Pasteur SA
Sapvax
SATT North SAS
Sellas Inc
Senhwa Biosciences Inc
Shenzen SiBiono GeneTech Co Ltd
Siamab Therapeutics Inc
Sigma-Tau SpA
SOM Biotech SL
Soricimed Biopharma Inc
Sorrento Therapeutics Inc
Sotio as
Spectrum Pharmaceuticals Inc
Sphaera Pharma Pvt Ltd
Starpharma Holdings Ltd